Last updated 2026-07-26
- Raised $500k grant, Feb 2022
- Raised $2M Seed round, Oct 2021
Total raised
$2.5M
Last: Grant 2022-03
Stage
Seed
Founded
2021
Headcount
6
HQ
Be'er Sheva, Israel
Sector
Health Tech & Life Sciences
About
Neuromagen Pharma is an early-stage pharmaceutical company developing a new class of innovative small molecules that activate telomerase reverse transcriptase (TERT), an enzyme that plays a major role in aging-related diseases and cellular senescence. The company's pipeline includes drugs for neurodegenerative diseases such as ALS and Alzheimer's, type 1 diabetes, fertility, and cardiovascular diseases. Their lead candidate, AGS-499, is being developed for Amyotrophic Lateral Sclerosis (ALS). The company's drug enhances the effectiveness of telomerase as a neuroprotectant, delaying the onset and progression of amyotrophic lateral sclerosis, enabling physicians to treat neurodegenerative diseases.
Funding history · 2 rounds · $2.5M total
2022-02
Grant
$500K
2021-10
Seed
$2.0M
Headcount over time
From 4 (2022-01) to 4 (2026-07) · +0 (+0%) · 7 points · source: Finder history + radar grounding
Q&A
- What is Neuromagen Pharma's primary focus?
- Neuromagen Pharma is an early-stage pharmaceutical company developing a new class of innovative small molecules that activate telomerase reverse transcriptase (TERT) for the treatment of aging-related and neurodegenerative diseases, including ALS and Alzheimer's.
- What is the status of Neuromagen Pharma's lead drug candidate, AGS-499?
- Neuromagen Pharma's lead candidate, AGS-499, is being developed for Amyotrophic Lateral Sclerosis (ALS) and received.
- How much funding has Neuromagen Pharma raised in total?
- Neuromagen Pharma has raised a total of $8,540,000 across multiple funding rounds.
- When did Neuromagen Pharma receive a grant from the Israel Innovation Authority?
- Neuromagen Pharma received a grant of $351,000 from the Israel Innovation Authority (IIA) in 2022 and another grant of $500,000 in March 2022.
- What was Neuromagen Pharma's most recent equity funding round?
- Neuromagen Pharma completed a Seed round in December 2024, raising $1,360,000.
- When is Neuromagen Pharma projected to close its Series A round?
- Neuromagen Pharma is projected to close an A Round in September 2025, aiming to raise $5,000,000.
- How many employees does Neuromagen Pharma currently have?
- Neuromagen Pharma has 1-10 employees.
- Who are the founders of Neuromagen Pharma?
- The founders of Neuromagen Pharma are Esther Priel, who also serves as CEO & CSO, and Gil Ben-Menachem, who also serves as CEO.
Team · 2
Esther Priel
Founder · Founder, CEO & CSO
Gil Ben-Menachem
Founder · Founder & CEO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCellsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
pharmaceuticalsamyotrophic-lateral-sclerosis-alsdegenerative-diseasesdrug-developmentcells
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | neuromagen.com/ |
|---|---|
| linkedin.com/company/80297359 |
Identifiers & details
| Legal name | Neuromagen Pharma Ltd. |
|---|---|
| Founded | 2021 |
| Employees (exact) | 6 |
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | neuromagen.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516401254 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2021-05-25 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 9 — annual_report (4), violation (1), shares_capital (2), people (2) |
| Registered address | חלקיקי האור 16 באר שבע |
Recent registry events
| Date | Event |
|---|---|
| 2026-05-31 | דו~ח שנתי-עדכון כתובת |
| 2026-05-31 | דו~ח שנתי-עדכון תחום עיסוק |
| 2026-05-31 | עדכון הפרה |
| 2026-05-31 | דו~ח שנתי-עדכון מען דיגיטלי |
| 2026-05-31 | דו~ח שנתי-שינוי בהוראות בתקנון |
| 2025-09-18 | העברת מניות |
| 2025-09-18 | הקצאת מניות |
| 2025-09-15 | עדכון בעלי תפקידים |
| 2025-10-05 | עדכון דירקטורים-הוספת דירקטור |